Username:

Password:
GO
Forgotten your login details? Click here

RECENT CLINICAL CANDIDATES AND SMR AWARD MEETING
Monday 4th December 2023
Friends House, 173-177 Euston Road, London NW1 2BJ
REGISTRATION NOW CLOSED
 

This meeting is supported by:

                                   

PROGRAMME

09.00 - 09.30 Arrival, registration and coffee
09.30 - 09.40 Welcome and introduction
Pam Brown, Pam Brown Consulting
 
Session 1
Chair:
Pam Brown, Pam Brown Consulting
09.40 - 10.20 1-1 Advancing the brain penetrant NLRP3 inhibitor NT-0796 into the clinic for the treatment of Parkinson's disease
Alan Watt, NodThera
10.20 - 11.00 1-2 DNA polymerase theta inhibition as a novel cancer therapy
Graeme Smith, Artios
 
11.00 - 11.30 Coffee break and exhibitors
 
Session 2
Chair:
Mike Hann, GSK
11.30 - 12.30 2-1 SMR Award lecture and presentation

The UK Vaccine Taskforce.
From inception to vaccination.
Vaccine Taskforce leadership team members:
Clive Dix, C4X Discovery
Ian McCubbin, Cell and Gene Therapy Catapult / RoslinCT
 
12.30 - 13.30 Lunch break and exhibitors
 
Session 3
Chair: David Hirst, MSD
13.30 - 14.10 3-1 Invention of MK-0616 a Macrocyclic Peptide Oral PCSK9 Inhibitor
Abbas Walji, MSD
14.10 - 14.50 3-2 Discovery of GSK3358699, a Mononuclear Myeloid-Targeted pan-BET Bromodomain Inhibitor
Phil Humphreys, GSK
 
14.50 - 15.20 Coffee break and exhibitors
 
Session 4
Chair: Mike Hann, GSK
15.20 - 16.00 4-1 Discovery of STC15, the First Molecule Specifically Targeting an RNA Methyltransferase Enzyme to Enter Clinical Development
Beth Thomas, Storm Therapeutics 
16.00 - 16.40 4-2 NXP800: a first-in-class, orally available, clinical-stage, investigational activator of the integrated stress response for treatment of ARID1A-mutated, platinum-resistant ovarian cancer
Prof Paul Workman, Centre for Cancer Drug Discovery, The Institute of Cancer Research (ICR), Sutton, London SW7 3RP
 
16.40 Closing remarks and meeting ends
Mike Hann, GSK
   

OVERVIEW
PROGRAMME